Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.75 |
| ▸ | CDK6 | Q00534 | 16/20 | 0.75 |
| ▸ | CDK2 | P24941 | 14/20 | 0.75 |
| ▸ | CDK1 | P06493 | 11/20 | 0.75 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.75 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.75 |
| ▸ | CCND3 | P30281 | 5/20 | 0.75 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.75 |
| ▸ | CDK7 | P50613 | 4/20 | 0.75 |
| ▸ | CDK9 | P50750 | 4/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | CIT | O14578 | 1/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.75 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.75 |
| ▸ | STK16 | O75716 | 1/20 | 0.75 |
| ▸ | CCNK | O75909 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29669642 | 1.00 | CDK4 (0.75) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL30459468 | 0.94 | CDK4 (0.84) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL30460094 | 0.94 | CDK4 (0.84) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL2490067 | 0.94 | CDK4 (0.84) | CDK4CDK6CDK2CDK1CCNB1 | |
| Trifluoroacetic Acid SCHEMBL30584528 | 0.90 | CDK4 (0.75) | CDK4CDK6CDK2CDK1CCNB1 | |
| Trifluoroacetic Acid SCHEMBL20838466 | 0.89 | CDK4 (0.74) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL22581106 | 0.89 | CDK4 (0.82) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL17488760 | 0.88 | CDK4 (0.88) | CDK4CDK6CDK2CDK1CCNB1 | |
| Trifluoroacetic Acid SCHEMBL29443175 | 0.87 | CDK4 (0.63) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL21658739 | 0.87 | CDK4 (0.87) | CDK4CDK6CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071552-B | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210340140-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-04 | — | — | US | disclosed |
| US-10865204-B2 | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190092768-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| WO-2017185031-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865204-B2 | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use | CDK6, CDK4, CDKL4 | CDK4 2/4885CDK6 1/4885CDK2 10/4885 |
| US-20210340140-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | CDK6, CDK4, CDKL4 | CDK4 2/4885CDK6 1/4885CDK2 10/4885 |
| US-20190092768-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | CDK6, CDK4, CDKL4 | CDK4 2/4885CDK6 1/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.